Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial

IMPORTANCE: Mavacamten, a cardiac myosin inhibitor, improved peak oxygen uptake (pVO(2)) in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in the EXPLORER-HCM study. However, the full extent of mavacamten’s effects on exercise performance remains unclear. OBJECTIVE: To inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Wheeler, Matthew T., Olivotto, Iacopo, Elliott, Perry M., Saberi, Sara, Owens, Anjali T., Maurer, Mathew S., Masri, Ahmad, Sehnert, Amy J., Edelberg, Jay M., Chen, Yu-Mao, Florea, Victoria, Malhotra, Rajeev, Wang, Andrew, Oręziak, Artur, Myers, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857843/
https://www.ncbi.nlm.nih.gov/pubmed/36652223
http://dx.doi.org/10.1001/jamacardio.2022.5099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857843/
https://www.ncbi.nlm.nih.gov/pubmed/36652223
http://dx.doi.org/10.1001/jamacardio.2022.5099

Ejemplares similares